Abstracts Archive - Page 1181 of 2607 - ACR Meeting Abstracts

Abstract Number: 674 • 2019 ACR/ARP Annual Meeting
Affordability Concerns Prevalent Among Patients with Systemic Lupus Erythematosus (SLE)
Kimberly DeQuattro¹, Laura Trupin ¹, Patricia Katz ¹, Stephanie Rush ¹, Louise Murphy ², Maria Dall'Era ¹ and Jinoos Yazdany ³, ¹University of California, San Francisco, San Francisco, CA, ²Centers for Disease Control and Prevention, Division of Population Health, Atlanta, ³UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: Among rheumatologic conditions, SLE is associated with very high healthcare and out of pocket costs. Little is known about patients’ concerns regarding costs of…
Abstract Number: 675 • 2019 ACR/ARP Annual Meeting
Clinical and Serological Lupus Activity Before and After Developing End Stage Renal Disease
Maria Salgado Guerrero¹, Alejandra Londono Jimenez ², Chrisanna Dobrowolsky ², Shudan Wang ², Wenzhu B. Mowrey ³ and Anna Broder ², ¹Internal Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²Rheumatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: SLE disease activity tends to diminish after the development of end stage renal disease (ESRD)1, 2. Nonetheless, some patients continue to show signs of…
Abstract Number: 676 • 2019 ACR/ARP Annual Meeting
Cluster Profiling of Patients in a Real-World Data Set with Systemic Lupus Erythematosus and Their Associated Treatments
Zahi Touma¹, Benjamin Hoskin ², Christian Atkinson ², David Bell ², Olivia Massey ³, Jennifer Lofland ⁴, Pamela Berry ⁵, Chetan Karyekar ⁶ and Karen Costenbader ⁷, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²Adelphi Real World, Cheshire, United Kingdom, ³Adelphi Real World, Bollington, United Kingdom, ⁴Janssen Scientific Affairs, LLC, Spring House, PA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA, ⁶Janssen Global Services, LLC, Horsham, PA, ⁷Brigham and Women's Hospital, Boston, MA
Background/Purpose: Previous systemic lupus erythematosus (SLE) studies have identified potential clusters of SLE clinical manifestations. To describe the presentation of SLE across different cohorts of patients…
Abstract Number: 677 • 2019 ACR/ARP Annual Meeting
Performance of Montreal Cognitive Assessment (MoCA) in Screening for Cognitive Impairment in Patients with Lupus Compared to the Neuropsychological Battery
Mahta Kakvan ¹, Robin Green ², Lesley Ruttan ³, Maria Tartaglia ⁴, Joan Wither ⁵, Moe Zandy ¹, Dennisse Bonilla ¹, May Choi ⁶, Jiandong Su ¹, Marvin Fritzler ⁶, Dorcas Beaton ⁷ and Zahi Touma¹, ¹University Health Network, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Toronto Rehabilitation Institute, Toronto, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵University Health Network, Krembil Research Institute, Toronto, ON, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁷St. Michael's Hospital, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is a common neuropsychological manifestation of Systemic Lupus Erythematosus (SLE) with a prevalence of 38% [95% confidence interval: 33,43%]. Previous studies,…
Abstract Number: 678 • 2019 ACR/ARP Annual Meeting
Performance of the EULAR/ACR 2019 Classification Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease
Martin Aringer¹, Ralph Brinks ², Karen Costenbader ³, David Daikh ⁴, Dimitrios Boumpas ⁵, David Jayne ⁶, Diane Kamen ⁷, Marta Mosca ⁸, Rosalind Ramsey-Goldman ⁹, Josef Smolen ¹⁰, David Wofsy ¹¹, Betty Diamond ¹², Søren Jacobsen ¹³, W Joseph McCune ¹⁴, Guillermo Ruiz-Irastorza ¹⁵, Matthias Schneider ¹⁶, Murray Urowitz ¹⁷, George Bertsias ¹⁸, Bimba Hoyer ¹⁹, Nicolai Leuchten ²⁰, Chiara Tani ²¹, Sara K. Tedeschi ²², Zahi Touma ¹⁷, Branimir Anic ²³, Florence Assan ²⁴, Daniel TM Chan ²⁵, Ann E Clarke ²⁶, Mary Crow ²⁷, László Czirják ²⁸, Andrea Doria ²⁹, Winfried Graninger ³⁰, Bernadette Halda-Kiss ³¹, Sarfaraz Hasni ³², Peter Izmirly ³³, Michelle Jung ²⁶, Gabor Kumanovics ³¹, Xavier Mariette ³⁴, Ivan Padjen ²³, Jose Maria Pego-Reigosa ³⁵, Juanita Romero-Diaz ³⁶, Iñigo Rua Figueroa ³⁷, Raphaèle Seror ²⁴, Georg Stummvoll ¹⁰, Yoshiya Tanaka ³⁸, Maria Tektonidou ³⁹, Carlos Vasconcelos ⁴⁰, Edward Vital ⁴¹, Daniel Wallace ⁴², Sule Yavuz ⁴³ Raymond Naden ⁴⁴, Thomas Dörner ⁴⁵ and Sindhu R. Johnson ⁴⁶, ¹Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, ²Department of Rheumatology and Hiller Research Unit of Rheumatology, UKD, Heinrich-Heine University, Düsseldorf, Germany, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴University of California at San Francisco and VA Medical Center, San Francisco, CA, ⁵University of Athens, Athens, Greece, ⁶Vasculitis and Lupus Clinic, Addenbrooke's Hospital, University of Cambridge, Cambridge, United Kingdom, ⁷Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁸Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ⁹Northwestern University, Chicago, IL, ¹⁰Medical University of Vienna, Vienna, Austria, ¹¹UCSF, San Francisco, ¹²Feinstein Institutes for Medical Research, Manhasset, ¹³Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ¹⁴University of Michigan, Ann Arbor, MI, ¹⁵Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, ¹⁶Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany, ¹⁷University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁸University of Crete, Rheumatology, Clinical Immunology and Allergy Unit, Heraklion, Greece, ¹⁹University of Schleswig-Holstein at Kiel, and Charité – Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Kiel, Germany, ²⁰University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²¹Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy, ²²Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ²³UHC Zagreb and University of Zagreb School of Medicine, Zagreb, Croatia, ²⁴Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, ²⁵University of Hong Kong, Hong Kong, Hong Kong, ²⁶University of Calgary, Calgary, AB, Canada, ²⁷Hospital for Special Surgery, New York, NY, ²⁸Dept. of Rheumatology and Immunology, University of Pécs, Pécs, Hungary, ²⁹University and Azienda Ospedaliera of Padova, Padova, Italy, ³⁰Medical University of Graz, Graz, Austria, ³¹University of Pécs, Pécs, Hungary, ³²NIAMS, National Institutes of Health, Bethesda, MD, ³³NYU School of Medicine, New York, ³⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ³⁵Complexo Hospitalario Universitario, Vigo, Spain, ³⁶Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ³⁷Hospital Doctor Negrin, Las Palmas, ³⁸University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³⁹First Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁴⁰University of Porto, UMIB Abel Salazar Biomedical Sciences Institute, Porto, Portugal, ⁴¹University of Leeds, Leeds, United Kingdom, ⁴²Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁴³Uppsala University, Istanbul, Turkey, ⁴⁴McMaster University, Hamilton, ON, Canada, ⁴⁵Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ⁴⁶Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada
Background/Purpose: The EULAR/ACR 2019 Classification Criteria for SLE have been validated in an international cohort of 696 SLE patients and 574 non-SLE patients with a…
Abstract Number: 679 • 2019 ACR/ARP Annual Meeting
Longitudinal Changes in Manifestations of SLE
Amanda Eudy¹, Jennifer Rogers ¹, Raeann Whitney ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹, David Pisetsky ², Rebecca Sadun ¹, Kai Sun ¹ and Megan Clowse ¹, ¹Duke University, Durham, ²Duke University, Durham VAMC, Durham
Background/Purpose: Our group has developed a conceptual model to categorize SLE manifestations into two dimensions termed Type 1 and Type 2. Type 1 SLE consists…
Abstract Number: 680 • 2019 ACR/ARP Annual Meeting
Patients Who Do Not Fulfill the 2018 EULAR/ACR Criteria for Systemic Lupus Erythematosus Accrue Less Damage: Data from a Multicenter, Multiethnic US Cohort
Manuel Ugarte-Gil¹, Guillermo Pons-Estel ², Luis Vilá ³, Russell Griffin ⁴ and Graciela Alarcón ⁵, ¹Universidad Científica del Sur, Lima, Peru, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ³University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham
Background/Purpose: The 2018 EULAR/ACR Criteria for the classification of patients with systemic lupus erythematosus (SLE) were proposed in order to improve the sensitivity and specificity…
Abstract Number: 681 • 2019 ACR/ARP Annual Meeting
Evaluation of the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Clinician Reported Outcome (ClinRO) and Patient Reported Outcome (PRO) in a Primarily Mestizo Population
Manuel Ugarte-Gil¹, Rocío-V. Gamboa-Cárdenas ², Cristina Reátegui-Sokolova ³, Victor Pimentel-Quiroz ⁴, Paola Zeña-Huancas ², Mariela Medina ², Claudia Elera-Fitzcarrald ¹, Samira García ³, Luciana Gil ², Erika Noriega ², Cesar Pastor-Asurza ³, Zoila Rodríguez-Bellido ², Joan Merrill ⁵, Anca Askanase ⁶, Graciela Alarcón ⁷ and Risto Perich-Campos ², ¹Universidad Científica del Sur, Lima, Peru, ²Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Lima, Peru, ³Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁴Hospital Nacional Guillermo Almenara Irigoyen - EsSalud, Lima, Lima, Peru, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶Columbia University, New York, ⁷University of Alabama at Birmingham, Birmingham
Background/Purpose: There are several instruments to measure disease activity in patients with systemic lupus erythematosus (SLE); however, none of them are able to capture all…
Abstract Number: 682 • 2019 ACR/ARP Annual Meeting
Correlation Between the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) and Health-Related Quality of Life (HRQoL) and Other PROs in a Primarily Mestizo Population
Manuel Ugarte-Gil¹, Rocío-V. Gamboa-Cárdenas ², Victor Pimentel-Quiroz ³, Cristina Reátegui-Sokolova ⁴, Paola Zeña-Huancas ², Mariela Medina ², Claudia Elera-Fitzcarrald ¹, Luciana Gil ², Samira García ⁴, Francisco Zevallos ⁴, Cesar Pastor-Asurza ⁴, Zoila Rodríguez-Bellido ², Anca Askanase ⁵, Joan Merrill ⁶, Graciela Alarcón ⁷ and Risto Perich-Campos ², ¹Universidad Científica del Sur, Lima, Peru, ²Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Lima, Peru, ³Hospital Nacional Guillermo Almenara Irigoyen - EsSalud, Lima, Lima, Peru, ⁴Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁵Columbia University, New York, ⁶Oklahoma Medical Research Foundation, Oklahoma City, ⁷University of Alabama at Birmingham, Birmingham
Background/Purpose: Disease activity in systemic lupus erythematosus (SLE) is understood differently by patients and physicians; furthermore, there are no reliable measures for patients to assess…
Abstract Number: 683 • 2019 ACR/ARP Annual Meeting
Biologic Differences Between Type 1 and 2 Lupus
Megan Clowse¹, Jennifer Rogers ¹, Amanda Eudy ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹, Rebecca Sadun ¹, Kai Sun ¹, Micah McClain ², Ephraim Tsalik ³, Chris Woods ², David Pisetsky ⁴, Prathyusha Bachali ⁵, Amrie Grammer ⁶, Michelle Catalina ⁵ and Peter Lipsky ⁷, ¹Duke University, Durham, ²Duke University & Duke Center for Applied Genomics & Precision Medicine, Durham, ³Duke University, Duke Center for Applied Genomics & Precision Medicine, Durham VA, Durham, ⁴Duke University, Durham VAMC, Durham, ⁵AMPEL BioSolutions and the RILITE Research Institute, Charlottesville, VA, ⁶AMPEL BioSolutions and the RILITE Research Institute, Charlottesville, ⁷AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: The manifestations of systemic lupus erythematosus (SLE) can be divided into categories according to a recently proposed model: a category of classic active autoimmune-driven…
Abstract Number: 684 • 2019 ACR/ARP Annual Meeting
Clinical Biomarkers at Renal Flare Are Associated with Histologic Changes in Repeat Renal Biopsy in Patients with Biopsy-proven Lupus Nephritis
Min Jung Kim¹, Hajeong Lee ¹, Yeong-Wook Song ¹ and Eun Bong Lee ², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul
Background/Purpose: Renal flares are common during treatment of biopsy-proven lupus nephritis (LN). However, it is unknown whether biopsy should be repeated in the event of…
Abstract Number: 685 • 2019 ACR/ARP Annual Meeting
Neutrophil Lymphocyte Ratio as a Marker for Immune Complex-Driven Inflammation in Patients with Systemic Lupus Erythematosus
Bobby Kwanghoon Han¹, Katherine Wysham ², Anders Bengtsson ³, Muhsen Al-Ani ¹, Grant Hughes ¹, Jenna Thomason ¹, Bernard Ng ⁴, Mark Wener ⁵ and Christian Lood ¹, ¹University of Washington, seattle, ²Veterans Health Administration Puget Sound, Seattle WA, Seattle, ³Lund University, Lund, Sweden, ⁴University of Washington, Veterans Affairs Puget Sound Health Care System, Seattle, WA, ⁵University of Washington, Seattle, WA
Background/Purpose: Neutrophils play a crucial role in pathogenesis of systemic lupus erythematosus (SLE). Recently, neutrophil to lymphocyte ratio (NLR) has been studied as a biomarker…
Abstract Number: 686 • 2019 ACR/ARP Annual Meeting
Association Between the Soluble Terminal Complement Complex C5b-9 (sC5b-9) and Signs of Active Kidney Disease in a Swiss SLE Cohort
Kristin Schmiedeberg ¹, Ruediger B. Mueller ², Thomas Neumann ¹, Ian Pirker ¹, Philipp Rein ³, Camillo Ribi ⁴, Andrea Rubbert-Roth ⁵, Michael Kirschfink ⁶, Reinhard Voll ⁷ and Johannes von Kempis¹, ¹Division of Rheumatology and Immunolog, Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland, ²Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, ³Division of Rheumatology and Immunolog, Kantonsspital St. Gallen, St.Gallen, Sankt Gallen, Switzerland, ⁴Service of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Vaud, Switzerland, ⁵Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland, ⁶Institute of Immunology, University of Heidelberg, Heidelberg, Germany, ⁷Division of Rheumatology and Clinical Immunology, Medical Centre - University of Freiburg, Freiburg, Germany
Background/Purpose: There is a lack of reliable biomarkers for disease activity in SLE. While C3a, an anaphylatoxin generated during of complement activation, could be predictive…
Abstract Number: 687 • 2019 ACR/ARP Annual Meeting
CCP Autoantibody Positive SLE Patients Show Unique Enrichments in SLE Criteria and Autoantibody Biomarkers That Vary by Race
John Goetzinger¹, Carla J. Guthridge ², Wade DeJager ², Eliza F. Chakravarty ³, Cristina Arriens ³, Teresa Aberle ², Aikaterini Thanou ², Joan T. Merrill ⁴ and Judith James ³, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Anti-cyclic citrullinated peptide (anti-CCP) antibodies are a hallmark of RA but are widely distributed in other autoimmune diseases. Although SLE is well characterized as…
Abstract Number: 688 • 2019 ACR/ARP Annual Meeting
Comparison of the Physicians’ Clinical Diagnosis and the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Multiethnic Cohort
Rosa Maria Serrano¹, Guillermo Pons-Estel ², Manuel Ugarte-Gil ³, Guillermina B Harvey ⁴, Daniel Wojdyla ⁵, Veronica Saurit ⁶, Enrique Soriano ⁷, Eloisa Bonfa ⁸, Loreto Massardo ⁹, Mario Cardiel ¹⁰, Rosana Quintana ¹, Graciela Alarcón ¹¹ and Bernardo A. Pons-Estel ¹², ¹Centro Regional de Enfermedades Autoinmunes y Reumáticas (CREAR), Grupo Oroño,Rosario, Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumaticas (CREAR),Grupo Oroño, Rosario, Rosario, Argentina, ³Universidad Científica del Sur, Lima, Peru, ⁴GLADEL, Rosario, Argentina, ⁵GLADEL Consultant, Rosario, Argentina, ⁶Hospital Privado, Centro Médico de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ⁷Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina, ⁸Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁹Centro de Biología Celular y Biomedicina, Facultad de Medicina y Ciencia. Universidad San Sebastián, Santiago, Chile., Santiago, Chile, ¹⁰Centro de Investigación Clínica de Morelia, SC, Morelia, México., Morelia, Mexico, ¹¹University of Alabama at Birmingham, Birmingham, ¹²Centro Regional de Enfermedades Autoinmunes y Reumáticas (CREAR), Grupo Oroño, Rosario, Rosario, Argentina
Background/Purpose: Diagnosis and classification of patients as having systemic lupus erythematosus (SLE) is critical in daily clinical practice as well as for clinical trials and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].